scholarly journals Accidental Overdose of Paliperidone Palmitate

2019 ◽  
Vol 2019 ◽  
pp. 1-3 ◽  
Author(s):  
Chiedozie Ojimba ◽  
Ayotomide Oyelakin ◽  
Taher Khandaker
Keyword(s):  
Side Effects ◽  
Plasma Level ◽  
Standard Dose ◽  
Selective Mutism ◽  
Paliperidone Palmitate ◽  
Receptor Sites ◽  
Schizophrenic Patients ◽  
Therapeutic Plasma Level ◽  
Disorganized Speech ◽  
Long Acting

Long-acting injectable (LAI) antipsychotics first introduced in 1960s are useful in the treatment of schizophrenic patients with poor medication adherence due to their maintaining feature of therapeutic plasma level without daily administration. Paliperidone Palmitate is one of such LAI antipsychotic drugs used due to its benefit of maintaining a therapeutic plasma level with four-week interval of injections. We report the case of a 21-year-old male with a history of mental illness that presented with selective mutism, disorganized speech, thought process and behavior, and auditory hallucinations who accidentally received 624 mg Paliperidone Palmitate intramuscularly with no reported side effects after 2 weeks of monitoring and observation. Paliperidone is a D2, 5HT2A receptor antagonist with additional antagonist activity at α-1 and α-2, H-1 receptor sites, and four metabolic pathways identified for its metabolism. Studies have reported adverse effects such as acute dystonia, acute renal failure, and cardiovascular abnormalities with Paliperidone overdose; however there is no reported literature on Paliperidone Palmitate overdose, though there have been reported cases of Paliperidone Palmitate side effects of hypersexuality and angioedema with the standard dose.

Drug defaulting by patients on long-acting phenothiazines

1973 ◽  
Vol 3 (1) ◽  
pp. 115-119 ◽  
Author(s):  
D. A. W. Johnson ◽  
Hugh Freeman
Keyword(s):  
Side Effects ◽  
Oral Medication ◽  
Medical Services ◽  
Schizophrenic Patients ◽  
Patient Refusal ◽  
Long Acting

SynopsisThis survey investigates drug defaulting by schizophrenic patients on a regime of long-term medication with injections of long-acting phenothiazines (LAP). Although the frequency of discontinuing LAP was appreciably less than reported in most surveys on oral medication, it remained a problem. An analysis of the reasons for patients discontinuing LAP identified several causes: patient-refusal, side-effects, failure of administration of the regime, and patients losing contact with the medical services by moving to other districts.

scholarly journals Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review

2021 ◽  
Vol 12 ◽  
Author(s):  
Amber N. Edinoff ◽  
Prithvi K. Doppalapudi ◽  
Claudia Orellana ◽  
Caroline Ochoa ◽  
Shelby Patti ◽  
...  
Keyword(s):  
Dose Interval ◽  
Paliperidone Palmitate ◽  
Critical Determinant ◽  
Once Daily ◽  
Schizophrenic Patients ◽  
Long Acting ◽  
Post Hoc ◽  
Antipsychotic Drug Treatment ◽  
Economic And Social Impacts ◽  
Risk Of Relapse

Given the typical age onset of schizophrenia, there are tremendous economic and social impacts that extend beyond the person and their families. One critical determinant of the diseases' impact is the patient's adherence to antipsychotic drug treatment. Approved in 2015 for the treatment of schizophrenia, paliperidone palmitate (Invega Trinza, a 3-month injection, noted as PP3M) is a second-generation long-acting injectable antipsychotic medication. Among the different formulations offered for palmitate paliperidone, including the 1 and 3-month formulations, the longer duration 3-month formulation was better at preventing relapse in schizophrenic patients. To date, different formulations of palmitate paliperidone that have been studied on relapse episodes of schizophrenia include once-daily extended-release oral paliperidone (ORAL paliperidone), once-monthly paliperidone palmitate (PP1M), and once-every-3-months paliperidone palmitate (PP3M). Post-hoc analyses show that patients who were withdrawn from PP1M paliperidone had the least risk of relapse, followed by patients withdrawn from PP3M and patients withdrawn from ORAL paliperidone. PP3M was better at preventing relapse compared to ORAL paliperidone. The results demonstrated that 50% of patients who were withdrawn from ORAL paliperidone, PP1M, or PP3M remained relapse-free for ~2, 6, and 13 months, respectively. Compared to PP1M, PP3M is just as safe and effective and has the added advantage of increased adherence related to a longer dose interval, decreasing the risk of relapse.

Paliperidone Palmitate and Quality of Life in Schizophrenia

2017 ◽  
Vol 41 (S1) ◽  
pp. S268-S268
Author(s):  
N.B. Juan Carlos ◽  
B. Girela ◽  
A. Maria Angeles
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Clinical Symptoms ◽  
Oral Treatment ◽  
Paranoid Schizophrenia ◽  
World Health ◽  
Paliperidone Palmitate ◽  
Double Blind ◽  
Schizophrenic Patients

There is growing interest in the study of the quality of life of mental disorders in general, and particularly in schizophrenia. The quality of life is defined by the world health organization as the perception that an individual has of his place in existence, in the context of culture and value system in which they live and in relation to its objectives, their expectations, their rules, their concerns. Paliperidone palmitate is a depot anti-psychotic treatment monthly application is indicated for maintenance treatment of schizophrenia in adult patients. In this work the quality of life in 5 subjects with a diagnosis of paranoid schizophrenia (less than 10 years of diagnosis) is evaluated, all males, aged between 42 and 45 years and with poor adherence to oral treatment. The patients received an average of paliperidone palmitate 100 mg/month. We evaluate the quality of life at baseline and after 3 months – BREF quality of life (WHOQOL – BREF) Scale Quality of Life (QOLS) and WHO was used. The results showed significant improvements in major QOLS scale in all subjects. There were no significant differences in total score WHOQL – BREF scale, but if there was improvement in the scores of some subscales. They no side effects evaluated in the UKU scale. The quality of life in schizophrenic patients can be affected by the presence of, particularly cognitive and negative clinical symptoms. New treatments as paliperidone palmitate improve adherence and have fewer side effects can improve the perceived quality of life. However, they need more extensive studies double-blind evaluation.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Drug information update: paliperidone palmitate for schizophrenia

2013 ◽  
Vol 37 (5) ◽  
pp. 164-166 ◽  
Author(s):  
Abraham M. Nussbaum ◽  
T. Scott Stroup
Keyword(s):  
Side Effects ◽  
Optimal Dose ◽  
Paliperidone Palmitate ◽  
Serum Prolactin ◽  
Sexual Side Effects ◽  
Study Results ◽  
The Us ◽  
Reported Study ◽  
Information Update ◽  
Long Acting

Aims and methodTo review the evidence for the use of paliperidone palmitate for people with schizophrenia and schizophrenia-like illnesses. We searched the Cochrane Schizophrenia Group Specialised Register and contacted the manufacturer of paliperidone palmitate, the US Food and Drug Administration, and the authors of papers that reported study results.ResultsBased on the evidence from five short-term, placebo-controlled studies, paliperidone palmitate is efficacious as an antipsychotic. Its adverse effects are similar to those of the closely related compounds paliperidone and risperidone. Extrapyramidal side-effects, weight gain and tachycardia are more common with paliperidone palmitate than placebo. Paliperidone palmitate was associated with substantial increases in serum prolactin but not with increased sexual side-effects in these studies. In two studies paliperidone palmitate was similar to depot risperidone.Clinical implicationsPaliperidone palmitate is an effective antipsychotic whose optimal dose appears to be between 39 and 234 mg every 4 weeks. We have no data assessing its long-term effectiveness or comparing it with any long-acting injected antipsychotic other than depot risperidone.

scholarly journals Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study

2020 ◽  
Vol 63 (1) ◽  
Author(s):  
Miquel Bioque ◽  
Eduard Parellada ◽  
Clemente García-Rizo ◽  
Sílvia Amoretti ◽  
Adriana Fortea ◽  
...  
Keyword(s):  
Side Effects ◽  
Psychotic Disorders ◽  
Rating Scale ◽  
Symptom Control ◽  
Combined Treatment ◽  
Mirror Image ◽  
Paliperidone Palmitate ◽  
Treatment Resistant ◽  
Image Study ◽  
Long Acting

Abstract Background: Around 30% of patients with schizophrenia are considered treatment resistant (TRS). Only around 40% of TRS patients respond to clozapine. Long acting injectable antipsychotics could be a useful augmentation strategy for nonresponders. Methods: We conducted a multicenter, observational, naturalistic, retrospective, 6-month mirror-image study to evaluate the efficacy and tolerability of clozapine and paliperidone palmitate association in 50 patients with TRS and other psychotic disorders. Clinical outcomes and side effects were systematically assessed. Results: Six months after starting the combined treatment, participants showed a significant relief of symptoms, decreasing the Brief Psychiatric Rating Scale total score from 18.32 ± 7.71 to 7.84 ± 5.16 (p < 0.001). The number of hospitalizations, the length of hospital stays and the number of visits to emergency services also decreased, while an increase of the functionality was observed (Personal and Social Performance total score increased from 46.06 ± 118.7 to 60.86 ± 18.68, p < 0.001). There was also a significant decrease in the number and severity of side effects with the combination therapy, decreasing the Udvalg for Kliniske Undersogelser total score from 10.76 ± 8.04 to 8.82 ± 6.63 (p = 0.004). Conclusions: This study provides the first evidence that combining clozapine with paliperidone palmitate in patients with TRS and other psychotic disorders could be effective and safe, suggesting further research with randomized controlled trials of augmentation strategies for clozapine nonresponder patients. Policy Significance Statement: Patients with psychotic disorders such as schizophrenia show a variable response to antipsychotic treatments. Around 30% of patients are considered treatment resistant, indicated by insufficient symptom control to at least two different drugs. In these resistant cases, clozapine should be indicated, as it has shown to be superior to other options. However, only 40% of patients respond to clozapine, being necessary to establish which treatments could best potentiate clozapine action. Combining clozapine with long acting injectable antipsychotics, and particularly paliperidone palmitate, could be a useful strategy. We conducted a multicenter study of 50 patients with treatment-resistant schizophrenia and other psychotic disorders comparing the efficacy and tolerability in the 6 month-period prior and after starting the clozapine and paliperidone palmitate association. Our study suggests that this combination could be effective and safer, laying the groundwork for future clinical trials with this combination.

Sign in / Sign up

Export Citation Format

Share Document